SMAD7 and renal fibrosis: First, consistent with a negative regulator of Smad7 in TGF-β/Smad signaling [10, 11], Smad7 may act by inhibiting the activation of TGF-β/Smad signaling, thereby blocking renal fibrosis, a major pathological feature of chronic AAN.